An experimental biotech drug being developed by Johnson & Johnson may offer hope to multiple myeloma patients who have run out of options, according to data from a midstage study released at a cancer meeting on Saturday. J&J plans to use the Phase II study to seek U.S. and European approval of its antibody daratumumab to treat the blood cancer. The drug received breakthrough designation from the U.S. Food and
Alastair Cook’s up-and-down England career makes his record-breaking feat all the more special, says Nasser Hussain.
(NaturalNews) The entire editorial board of the Washington Post functions as a group of hilarious quack science Monsanto operatives pretending to be engaged in reporting real news. It’s so bad that key articles published by the Post now appear to be “written” by Monsanto, with the…
(NaturalNews) The entire editorial board of the Washington Post functions as a group of hilarious quack science Monsanto operatives pretending to be engaged in reporting real news. It’s so bad that key articles published by the Post now appear to be “written” by Monsanto, with the…